TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
Abstract Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, and ranks among the most lethal malignancies globally, primarily due to its high rates of recurrence and metastasis. Despite the urgency, no reliable biomarkers currently exist for predicting tumor recurrence in HCC....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-87545-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571712077561856 |
|---|---|
| author | Jin Li Ling Bai Zhaodan Xin Jiajia Song Hao Chen Xingbo Song Juan Zhou |
| author_facet | Jin Li Ling Bai Zhaodan Xin Jiajia Song Hao Chen Xingbo Song Juan Zhou |
| author_sort | Jin Li |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, and ranks among the most lethal malignancies globally, primarily due to its high rates of recurrence and metastasis. Despite the urgency, no reliable biomarkers currently exist for predicting tumor recurrence in HCC. Telomerase reverse transcriptase (TERT) promoter mutations (TERTpm) and cellular tumor antigen p53 mutations (TP53m) have been frequently documented in HCC, but their combined clinical significance remains undefined. In this study, we investigated the clinical implications of TERTpm, TP53m, and their co-occurrence in 50 HCC tissue samples using the next-generation sequencing (NGS) technology. We identified TERTpm (C228T) and TP53m in 16 (32%) and 24 (48%) samples, respectively. Our findings indicate that these mutations are more prevalent in male patients (100% for TERTpm, 83.33% for TP53m), in those with solitary tumors (87.5% for both), in individuals with G2-G3 hepatitis (100% / 83.3%), and in cases of moderately differentiated tumors (75.0% / 83.3%). Furthermore, patients with both TERTpm and TP53m exhibited a significantly higher risk of tumor relapse (P < 0.05) and shorter progression-free survival (P < 0.05). Collectively, our results suggest that presence of both TERTpm and TP53m may serve as a robust predictor of tumor recurrence and a marker of poor prognosis in HCC. |
| format | Article |
| id | doaj-art-2ff1f6d660d74f16bb3d496ec8edb0d0 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-2ff1f6d660d74f16bb3d496ec8edb0d02025-02-02T12:21:30ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-025-87545-zTERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosisJin Li0Ling Bai1Zhaodan Xin2Jiajia Song3Hao Chen4Xingbo Song5Juan Zhou6Department of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityAbstract Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, and ranks among the most lethal malignancies globally, primarily due to its high rates of recurrence and metastasis. Despite the urgency, no reliable biomarkers currently exist for predicting tumor recurrence in HCC. Telomerase reverse transcriptase (TERT) promoter mutations (TERTpm) and cellular tumor antigen p53 mutations (TP53m) have been frequently documented in HCC, but their combined clinical significance remains undefined. In this study, we investigated the clinical implications of TERTpm, TP53m, and their co-occurrence in 50 HCC tissue samples using the next-generation sequencing (NGS) technology. We identified TERTpm (C228T) and TP53m in 16 (32%) and 24 (48%) samples, respectively. Our findings indicate that these mutations are more prevalent in male patients (100% for TERTpm, 83.33% for TP53m), in those with solitary tumors (87.5% for both), in individuals with G2-G3 hepatitis (100% / 83.3%), and in cases of moderately differentiated tumors (75.0% / 83.3%). Furthermore, patients with both TERTpm and TP53m exhibited a significantly higher risk of tumor relapse (P < 0.05) and shorter progression-free survival (P < 0.05). Collectively, our results suggest that presence of both TERTpm and TP53m may serve as a robust predictor of tumor recurrence and a marker of poor prognosis in HCC.https://doi.org/10.1038/s41598-025-87545-zHCCTERT promoter mutationTP53 mutationRecurrencePrognosis |
| spellingShingle | Jin Li Ling Bai Zhaodan Xin Jiajia Song Hao Chen Xingbo Song Juan Zhou TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis Scientific Reports HCC TERT promoter mutation TP53 mutation Recurrence Prognosis |
| title | TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| title_full | TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| title_fullStr | TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| title_full_unstemmed | TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| title_short | TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| title_sort | tert tp53 mutations a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis |
| topic | HCC TERT promoter mutation TP53 mutation Recurrence Prognosis |
| url | https://doi.org/10.1038/s41598-025-87545-z |
| work_keys_str_mv | AT jinli terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT lingbai terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT zhaodanxin terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT jiajiasong terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT haochen terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT xingbosong terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis AT juanzhou terttp53mutationsanovelbiomarkerpairforhepatocellularcarcinomarecurrenceandprognosis |